Garcinoic acid
Garcinoic acid is an orally active anti-inflammatory agent that crosses the blood-brain barrier. Garcinoic acid also enhances efferocytosis and enzyme/receptor regulation, and selectively inhibits human COX-2, porcine α-amylase, Saccharomyces cerevisiae α-glucosidase and human DNA polymerase β (IC50=11 μM), as well as activates human PXR. Garcinoic acid enhances macrophage efferocytosis via receptors such as MerTK and LRP-1, and promotes the production of pro-resolving lipid mediators. Garcinoic acid inhibits NF-κB activation and pro-inflammatory cytokine secretion, interferes with Aβ aggregation, downregulates NLRP3 inflammasome activity, and binds to targets including CD44 and EGFR to inhibit leukemia cell proliferation. The pharmacological activities of Garcinoic acid, such as antioxidant, anti-inflammatory and lipid metabolism-regulating effects, are widely used in studies related to various diseases including atherosclerosis, Alzheimer's disease, type 2 diabetes, inflammatory bowel disease and viral pneumonia.
For research use only. We do not sell to patients.
- CAS No.: 91893-83-3
- Formula: C27H38O4
- Molecular Weight:426.59
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All DNA/RNA Synthesis Isoforms
More
Biological Activity
|
hCOX-2 |
Garcinoic acid (2.5 μM; 24 h, 14-24 h) inhibits LPS-induced Cox2 and iNos protein expression in murine RAW264.7 macrophages, reducing iNos levels to 17% of LPS control at 2.5 μM[1].
Garcinoic acid (0.02-100 μM; 72 h incubation with cells, following 24 h initial cell culture) inhibits proliferation of KASUMI-1, HL-60, THP-1, RS4;11, and MOLT-4 leukemia cell lines with IC50 values ranging from 18.04 μM to 49.01 μM, showing the strongest activity against HL-60 cells[2].
Garcinoic acid (0.25-5 μM; 24 h) does not reduce the viability of mouse bone marrow-derived macrophages[3].
Exogenous Lipoxin A4 (100 nM; 2 h) or Resolvin E1 (10 nM; 30 min) restores garcinoic acid (1 μM; 24 h)-enhanced efferocytosis in mouse bone marrow-derived macrophages with Nrf2 silenced or HO-1 inhibited[3].
Garcinoic acid (1-50 μM; 24 h) dose-dependently upregulates PXR, CYP3A4, and MDR1 expression in HepG2 cells, with the response dependent on functional PXR[5].
Garcinoic acid (25 μM; 24 h pre-incubation, 24 h incubation with Aβ(1-42)) restores and stimulates ApoE efflux in mouse cortical astrocytes via a PPARγ-independent mechanism, up-regulates PPARγ and PXR expression, and increases expression of the PXR-regulated genes CYP4F2 and MDR1 in these cells at 25 μM[6].
Garcinoic acid (5 μM; 6 h) suppresses cleavage of GSDMD into the pyroptosis-inducing NT-GSDMD fragment in LPS/ATP-stimulated murine J774A.1 macrophages after 6 hours of total incubation[8].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:murine RAW264.7 macrophages
-
Concentration:2.5 μM
-
Incubation Time:24 h (pre-incubated); 14 h (co-incubated with LPS for Cox2); 24 h (co-incubated with LPS for iNos)
-
Result:Did not detectably modulate basal Cox2 or iNos protein levels.
Reduced Cox2 protein expression to 67% relative to LPS-only controls.
Reduced iNos protein expression to 17% relative to LPS-only controls.
-
Cell Line:KASUMI-1, HL-60, THP-1, RS4;11, MOLT-4
-
Concentration:0.02-100 μM
-
Incubation Time:72 h (incubation with cells, following 24 h initial cell culture)
-
Result:Inhibited proliferation of KASUMI-1 cells, with an IC50 value of 30.81 μM.
Inhibited proliferation of HL-60 cells, with an IC50 value of 18.04 μM.
Inhibited proliferation of THP-1 cells, with an IC50 value of 49.01 μM.
Inhibited proliferation of RS4;11 cells, with an IC50 value of 42.87 μM.
Inhibited proliferation of MOLT-4 cells, with an IC50 value of 26.73 μM.
-
Cell Line:mouse bone marrow-derived macrophages (BMDMs)
-
Concentration:0.25-5 μM
-
Incubation Time:24 h
-
Result:Showed no cytotoxic effect on BMDMs, with cell viability remaining near 100% across all groups.
Garcinoic acid (1 mg/kg; i.p.; daily; from 7 days pre-DSS exposure until study end) attenuates DSS (HY-116282C)-induced colitis in male C57BL/6 mice by restoring efferocytosis, increasing specialized pro-resolving lipid mediator levels, and activating Nrf2 signaling[3].
Garcinoic acid (5-100 mg; p.o.; single bolus) acts as a selective PXR agonist in mice, dose-dependently increasing PXR, CYP3A11, and MDR1 expression in liver and intestinal tissue at well-tolerated doses ≤25 mg, while higher doses cause mortality[5].
Garcinoic acid (5-25 mg; p.o.; single dose) dose-dependently up-regulates PPARγ, ApoE, and PXR expression in the brain of healthy C57Bl/6 mice, with significant effects observed at doses ≥5 mg[6].
Garcinoic acid (200 mg/kg; p.o.; daily; 10 days) significantly reduces amyloid β plaque number and deposition in the brain of TgCRND8 Alzheimer's disease model mice, while up-regulating ApoE and MDR1 expression[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57Bl/6 background (8-week-old male, 25-28 g, apolipoprotein E knockout, high fat diet-fed for 8 weeks)[1]
-
Dosage:1 mg/kg
-
Administration:i.p.; weekly; 8 weeks
-
Result:Decreased intra-plaque nitrotyrosine levels to 50% of control levels.
Downregulated blood CD4 positive T cells by 14.8%.
Increased blood natural killer (NK) cells from 3.2% to 5.6%.
Increased blood natural killer T (NKT) cells from 0.2% to 0.6%.
Upregulated spleen NK cells from 2.0% to 2.8%.
Showed no significant changes in body/organ weight, plasma lipid profile, total lesion size, necrotic core area, lipid content, collagen content, VCAM-1 levels, CD68 levels, MCP-1 levels, IL1β levels, plasma NO levels, or plasma prostanoid levels.
-
Animal Model:C57BL/6 (5-week-old male; DSS-induced colitis)[3]
-
Dosage:1 mg/kg
-
Administration:i.p.; daily; from 7 days pre-DSS exposure until study end
-
Result:Prevented DSS-induced reduction in colon length.
Increased body weight compared to DSS-only mice.
Reduced Disease Activity Index (DAI) scores compared to DSS-only mice.
Restored colonic tissue architecture, reducing epithelial degeneration, inflammatory cell infiltration, and crypt loss compared to DSS-only mice.
Increased the ratio of macrophage-associated apoptotic cells to free apoptotic cells in colon tissue, restoring efferocytosis to control levels.
Increased plasma levels of Lipoxin A4, Resolvin D2, and Resolvin E1 compared to DSS-only mice.
Increased colon tissue levels of Lipoxin A4, Resolvin D2, and Resolvin E1 compared to DSS-only mice.
Increased colon tissue protein levels of Nrf2 and NAD(P)H:quinone oxidoreductase (NQO1) compared to control mice.
-
Animal Model:TgCRND8 transgenic (5-month-old, 14-15-month-old)[6]
-
Dosage:200 mg/kg
-
Administration:p.o.; daily; 10 days
-
Result:Reduced 10-50 μm2 amyloid β plaques from ~400 to ~300, 50-200 μm2 plaques from ~100 to ~50, and 200-400 μm2 plaques from ~50 to ~10 (all significant vs. untreated Tg mice, p < 0.05 or p < 0.005) in 14-15-month-old Tg mice.
Confirmed decreased amyloid β deposition in both 5-month-old and 14-15-month-old Tg mice via Congo Red staining.
Increased ApoE and MDR1 expression in the hippocampus of Tg mice significantly.
Reached concentrations between 0.8 and 10.3 ppm (ng/mg of proteins) in the parietal cortex and hippocampus of treated Tg mice.
Chemical Information
-
CAS No. 91893-83-3
-
Molecular Weight 426.59
-
Formula C27H38O4
-
SMILES
CC1=C2C(CC[C@](C)(O2)CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/C(O)=O)=CC(O)=C1
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Wallert M, et al. The vitamin E derivative garcinoic acid from Garcinia kola nut seeds attenuates the inflammatory response. Redox Biol. 2019;24:101166. [Content Brief]
[3]. Isot I, et al. Garcinoic acid enhances inflammation resolution against colitis by activating Nrf2 dependent efferocytosis. Free Radic Biol Med. 2025;237:37-45. [Content Brief]
[4]. Olajide OA, et al. Garcinia kola and garcinoic acid suppress SARS-CoV-2 spike glycoprotein S1-induced hyper-inflammation in human PBMCs through inhibition of NF-κB activation. Phytother Res. 2021;35(12):6963-6973. [Content Brief]
[5]. Bartolini D, et al. Garcinoic Acid Is a Natural and Selective Agonist of Pregnane X Receptor. J Med Chem. 2020;63(7):3701-3712. [Content Brief]
[6]. Marinelli R, et al. Garcinoic acid prevents β-amyloid (Aβ) deposition in the mouse brain. J Biol Chem. 2020;295(33):11866-11876. [Content Brief]
[7]. Sabbatini S, et al. Modulation of C. albicans-Induced Immune Response in Vaginal Epithelial Cells by Garcinoic Acid. Microorganisms. 2024 Nov 29;12(12):2455. [Content Brief]
[8]. Börmel L, et al. The Vitamin E Derivative Garcinoic Acid Suppresses NLRP3 Inflammasome Activation and Pyroptosis in Murine Macrophages. Inflammation. 2025;48(5):3340-3352. [Content Brief]
[9]. Gujarathi S, et al. A Facile Semisynthesis and Evaluation of Garcinoic Acid and Its Analogs for the Inhibition of Human DNA Polymerase β. Molecules. 2020;25(24):5847. Published 2020 Dec 11. [Content Brief]
[10]. Terashima K, et al. Powerful antioxidative agents based on garcinoic acid from Garcinia kola. Bioorg Med Chem. 2002;10(5):1619-1625. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Garcinoic acid Related Classifications
HY-N9454 Related Classifications
Powered by Bioz